Maternal RSV Vaccine and Nirsevimab Show Similar Protection Against Infant Infection
Maternal vaccination during pregnancy and a monoclonal antibody given to infants offer similar protection against respiratory syncytial virus infection and hospitalization among full-term infants. Maternal RSV Vaccine and Nirsevimab Show Similar Protection Against Infant Infection In a large cohort study, maternal respiratory syncytial virus (RSV) prefusion F (preF) vaccination and infant nirsevimab offered similar protection against RSV infection and hospitalization in full-term infants. Compared with no protection, both interventions reduced RSV infections by more than 65% and hospitalizations by more than 70%. - Researchers conducted a retrospective cohort study of 18,835 full-term infants born at Kaiser Permanente Northern California between December 2023 and March 2024 or between September 2024 and March 2025. - Infants protected by maternal RSVpreF (administered at 32-36 weeks'…